Actively Recruiting
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Led by Nantes University Hospital · Updated on 2024-05-07
2100
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.
CONDITIONS
Official Title
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux
You will not qualify if you...
- Patients treated with unfractionated heparin or low molecular weight heparin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nantes University Hospital
Nantes, Loire-Atlantique, France, 44093
Actively Recruiting
Research Team
E
Elodie BOISSIER
CONTACT
A
Annick COULON
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here